NCT00352859View on ClinicalTrials.gov

Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib

PHASE4TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

August 31, 2006

Study Completion Date

November 30, 2006

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon

Continue sorafenib with addition of gemcitabine or interferon

DRUG

Gemcitabine or Interferon (only)

Discontinue Sorafenib and receive Gemcitabine or Interferon only

Trial Locations (1)

Unknown

Kansas City

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00352859 - Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib | Biotech Hunter | Biotech Hunter